Format – Fireside chat and one-on-one investor meetings Date and Time – Wednesday, June 11, 2025, at 8:40am ET / 5:40am PT Live webcasts of the data release, as well as the presentation ...

a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT. During the webcast, members of Anaptys management ...

PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body's ability to fight cancer. Combining ...

mediated by engagement of PD-1 by PD-L1 and PD-L2. The structural conservation of B7-like and CD28-like receptors may reflect the distance between T cells and APCs in the immunological synapse.

Two-part preclincal and clinical development programme launched to assess potential benefits of administering S-pindolol benzoate during and post-GLP-1 receptor agonist therapy to improve muscle ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...

AnaptysBio offers significant upside, with fair value estimates nearly double its current market cap if RA approval is ...

Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that its third drug candidate, RM-0256, has been ...

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and ...